To delineate the relevance of AKT and ERK1/2 activation with outcome in cisplatin-treated cervical cancer patients, the patients in TCGA dataset were divided into two groups according to disease-free survival (DFS) time: good prognosis (DFS time > 3 years) and poor prognosis groups (DFS time < 3 years). Here, MAPK3 is linked to cervical cancer.